The company has seen a mixed track record when it comes to current year estimate revisions over the past few weeks. There has been no estimate revision on either side, and the consensus for loss estimates has widened marginally. This recent price action is discouraging, so make sure to keep a close watch of this firm in the near future, and especially on earnings estimates following the recent slump.
SNTA currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Some better-ranked stocks in the healthcare sector include Alexion Pharmaceuticals, Inc. (ALXN), Alkermes plc (ALKS) and Emergent BioSolutions, Inc. (EBS). All these stocks hold a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment